Archival ReportMedication for Attention-Deficit/Hyperactivity Disorder and Risk for Depression: A Nationwide Longitudinal Cohort Study
Section snippets
Study Population
We used data from several population-based registers in Sweden, which were linked with unique personal identification numbers (22). The study participants were identified from the National Patient Register, which has nationwide coverage of information on psychiatric inpatient care since 1973 and outpatient visits to specialists (not general practitioners) since 2001. We identified 38,752 patients with a clinical diagnosis of ADHD (ICD-10 code F90) who were born between 1960 and 1998 and were
Results
Table 1 lists the descriptive statistics for all patients included in this study. We identified 38,752 patients with ADHD, of whom 2987 experienced depression events in 2009. Among male patients, 16.8% received ADHD medication on January 1, 2006, and 51.3% received ADHD medication at least once during the period between January 1, 2006, and December 31, 2008, with median length of treatment of 1.2 years (interquartile range, 0.5–2.4 years). Corresponding figures in female patients were 10.9%,
Discussion
In this large, population-based cohort study, we followed 38,752 patients with ADHD for 4 years to investigate the association between ADHD medication and depression. The results suggested that ADHD medication was associated with a reduced long-term risk of depression after adjustment for sociodemographic and clinical confounders. The risk was lower for longer duration of ADHD medication. In addition, ADHD medication was associated with reduced rates of concurrent depression, even when using
Acknowledgments And Disclosures
This work was supported by the Swedish Research Council Grant No. 2013-2280, Swedish Initiative for Research on Microdata in the Social And Medical Sciences framework Grant No. 340-2013-5867, National Institute of Mental Health Grant No. 1R01MH102221, Swedish Research Council for Health, Working Life and Welfare Grant No. 2014-2780 (to ZC), and Indiana Clinical and Translational Sciences Institute Grant No. TL1 TR001107 (to PDQ). The funders had no role in study design, data collection and
References (37)
- et al.
Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: A nationwide cohort study
Lancet
(2015) - et al.
Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood
Biol Psychiatry
(2003) - et al.
Enduring behavioral effects of early exposure to methylphenidate in rats
Biol Psychiatry
(2003) - et al.
Effects of long-term methylphenidate treatment in adolescent and adult rats on hippocampal shape, functional connectivity and adult neurogenesis
Neuroscience
(2015) - et al.
Drug-induced depression: A case/non case study in the French Pharmacovigilance Database
Therapie
(2015) - et al.
Signal detection of methylphenidate by comparing a spontaneous reporting database with a claims database
Regul Toxicol Pharmacol
(2011) - et al.
Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: A review of controlled and naturalistic studies
Eur Neuropsychopharmacol
(2013) - et al.
3-year follow-up of the NIMH MTA study
J Am Acad Child Adolesc Psychiatry
(2007) - et al.
Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment
J Am Acad Child Adolesc Psychiatry
(2004) - et al.
Depression and violence: A Swedish population study
Lancet Psychiatry
(2015)
The worldwide prevalence of ADHD: Is it an American condition?
World Psychiatry
Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: An overview
J Clin Psychiatry
Comorbidity
J Child Psychol Psychiatry
Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder
J Clin Psychiatry
A review of co-morbid depression in pediatric ADHD: Etiology, phenomenology, and treatment
J Child Adolesc Psychopharmacol
Does pharmacotherapy for attention-deficit/hyperactivity disorder predict risk of later major depression?
J Child Adolesc Psychopharmacol
Assessment and treatment of attention deficit hyperactivity disorder in children with comorbid psychiatric illness
Curr Opin Pediatr
National trends in psychotropic medication use in young children: 1994-2009
Pediatrics
Cited by (82)
Depression in young people
2022, The LancetADHD co-morbidities: A review of implication of gene × environment effects with dopamine-related genes
2022, Neuroscience and Biobehavioral ReviewsEvidence-based pharmacological treatment options for ADHD in children and adolescents
2022, Pharmacology and TherapeuticsThe Combined Effects of Young Relative Age and Attention-Deficit/Hyperactivity Disorder on Negative Long-term Outcomes
2022, Journal of the American Academy of Child and Adolescent PsychiatryAdult ADHD in the Republic of Ireland: The evolving response
2023, BJPsych Bulletin